| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
PYPD
PolyPid
|
Oct 29, 2026 | BUY |
Strong Buy
+191.6% avg upside
7 analysts
|
$8.00
48.41% Upside
|
+17.0% | Β· |
|
RNA
Atrium Therapeutics, Inc.
|
Oct 22, 2026 | BUY |
Strong Buy
+246.6% avg upside
6 analysts
|
$15.00
81.35% Upside
|
-20.6% | Β· |
|
COYA
Coya Therapeutics, Inc.
|
Oct 15, 2026 | BUY |
Strong Buy
+343.2% avg upside
7 analysts
|
$12.00
232.48% Upside
|
-30.4% | Β· |
|
NRSN
Neurosense Therapeutics Ltd.
|
Oct 13, 2026 | HOLD |
Strong Buy
+4265.6% avg upside
5 analysts
|
$3.50
75.97% Upside
|
-49.6% | Β· |
|
CRVO
CervoMed
|
Oct 13, 2026 | BUY |
Strong Buy
+1040.3% avg upside
9 analysts
|
$7.00
337.59% Upside
|
-19.4% | Β· |
|
CAPR
Capricor Therapeutics
|
Oct 06, 2026 | HOLD |
Strong Buy
+332.5% avg upside
12 analysts
|
$7.00
9.77% Upside
|
+8.5% | Β· |
|
CH:NWRN
Newron Pharmaceuticals SpA
|
Oct 05, 2026 | BUY |
Strong Buy
+203.1% avg upside
4 analysts
|
$19.00
111.14% Upside
|
+12.0% | Β· |
|
LBRX
LB Pharmaceuticals, Inc.
|
Oct 05, 2026 | HOLD |
Strong Buy
+47.7% avg upside
11 analysts
|
$35.00
11.79% Downside
|
+16.4% | Β· |
|
MNOV
Medicinova
|
Sep 19, 2026 | BUY |
Strong Buy
+411.9% avg upside
6 analysts
|
$6.00
328.62% Upside
|
-59.4% | Β· |
|
ABEO
Abeona Therapeutics
|
Sep 19, 2026 | BUY |
Strong Buy
+295.1% avg upside
18 analysts
|
$17.00
290.78% Upside
|
-54.5% | Β· |
|
ANVS
Annovis Bio
|
Sep 04, 2026 | BUY |
Strong Buy
+1922.3% avg upside
8 analysts
|
$7.00
519.44% Upside
|
-46.8% | Β· |
|
OVID
Ovid Therapeutics
|
Sep 03, 2026 | BUY |
Strong Buy
+103.8% avg upside
19 analysts
|
$8.00
214.95% Upside
|
-20.1% | Β· |
|
IMUX
Immunic
|
Sep 01, 2026 | BUY |
Strong Buy
+399.8% avg upside
23 analysts
|
$29.00
286.18% Upside
|
-49.7% | Β· |
|
CING
Cingulate Inc
|
Aug 24, 2026 | BUY |
Strong Buy
+306.6% avg upside
5 analysts
|
$9.00
80.74% Upside
|
-24.3% | Β· |
|
PMN
ProMIS Neurosciences
|
Aug 21, 2026 | BUY |
Strong Buy
+1862.7% avg upside
9 analysts
|
$29.00
776.20% Upside
|
-77.9% | Β· |
|
LGVN
Longeveron
|
Aug 19, 2026 | BUY |
Strong Buy
+4590.7% avg upside
4 analysts
|
$30.00
1696.49% Upside
|
-65.5% | Β· |
|
GANX
Gain Therapeutics
|
Aug 18, 2026 | BUY |
Strong Buy
+596.9% avg upside
9 analysts
|
$8.00
607.95% Upside
|
-42.4% | Β· |
|
TRDA
Entrada Therapeutics Inc
|
Aug 12, 2026 | BUY |
Strong Buy
+370.4% avg upside
10 analysts
|
$11.00
142.53% Upside
|
-35.3% | Β· |
|
RVPH
Reviva Pharmaceuticals Holdings
|
Apr 01, 2026 | BUY |
Strong Buy
+12423.8% avg upside
9 analysts
|
$1.00
185.69% Upside
|
-52.0% | Β· |
|
ENSC
Ensysce Biosciences
|
May 20, 2024 | HOLD |
Buy
+1919.0% avg upside
4 analysts
|
β | Β· | Β· |
|
BWAY
Brainsway
|
May 20, 2024 | HOLD |
Strong Buy
+25.4% avg upside
10 analysts
|
β | +94.9% | Β· |
|
SPRB
Spruce Biosciences
|
May 20, 2024 | HOLD |
Strong Buy
+130.2% avg upside
16 analysts
|
β | Β· | Β· |
|
ANEB
Anebulo Pharmaceuticals
|
May 20, 2024 | HOLD |
Buy
+1289.6% avg upside
5 analysts
|
β | -53.0% | Β· |
|
PXMD
PaxMedica, Inc.
|
May 20, 2024 | HOLD |
Hold
1 analyst
|
β | Β· | Β· |
|
TSE:CSCI
COSCIENS Biopharma
|
May 20, 2024 | HOLD |
Strong Buy
+102.4% avg upside
8 analysts
|
β | Β· | Β· |
|
RKTO
Rocket One
|
May 20, 2024 | HOLD |
Strong Buy
+2130.8% avg upside
8 analysts
|
β | -29.5% | Β· |
|
DMRA
Damora Therapeutics
|
Oct 24, 2023 | HOLD |
Strong Buy
+39.9% avg upside
20 analysts
|
β | -48.8% | Β· |
|
OBX
Obsidian Therapeutics
|
Sep 19, 2023 | HOLD |
Strong Buy
+14.6% avg upside
11 analysts
|
$0.30
97.99% Downside
|
Β· | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.